Thousands of NHS cancer patients throughout England are poised to benefit from a transformative shift to their care pathway, as a faster injectable form of the globally leading cancer drug is now available on the health service. Keytruda, an immunotherapeutic agent currently deployed to fight 14 distinct forms of cancer, has been delivered through intravenous drip for close to ten years—a process that could take over an hour in hospital. The new injectable version, however, can be delivered in just minutes, promising to substantially cut patients’ hours spent in hospital chairs and free up valuable NHS resources. Initial patients, including 86-year-old Shirley Xerxes from Hertfordshire, have already witnessed the change firsthand.
A transformative shift in cancer care provision
The launch of injectable Keytruda represents a significant change in operations for NHS cancer centres across England. Where patients traditionally needed lengthy hospital visits for intravenous infusions running longer than an hour, the new injection method shortens the complete treatment to just one or two minutes, according to the treatment schedule. This streamlining is especially advantageous given that approximately 14,000 cancer patients in England commence Keytruda treatment annually, with the overwhelming majority expected to move to the injectable form. The efficiency gains reach beyond patient convenience, releasing hospital pharmacy teams from the time-consuming task of preparing sterile infusion bags and enabling clinical staff to direct their time more efficiently across busy cancer centres.
NHS England’s chief clinical director for cancer, Professor Peter Johnson, has highlighted the twin advantages of this shift. The move towards a standard, rapid injection not only improves the patient experience but also streamlines clinical workflows and resource management. For patients like Shirley Xerxes, the practical impact is significant—what once required a significant amount of her day now requires mere minutes, permitting her to free up time for personal activities and sustain her wellbeing between treatments. This marks the third immunotherapy injection option now provided through the NHS, following the rollout of Opdivo in injection form at select hospitals the previous year, signalling a wider movement towards patient-centred, efficient cancer care delivery.
- Injectable administered once every three weeks as one-minute injection
- Optional six-weekly dosing available as a two-minute administration
- Around 14,000 patients annually qualified for therapy
- Effective against 14 distinct cancer varieties such as lung and breast
How immune-based therapy helps defeat cancer
Keytruda is part of a category of drugs known as immunotherapy, which harnesses the body’s own immune system to identify and eliminate cancer cells. Cancer cells are remarkably deceptive—they generate proteins that effectively send a “stop signal” to immune cells, preventing the body from mounting an effective defence. Scientists frequently characterise this mechanism as cancer hiding behind an “invisibility cloak”, enabling malignant cells to evade detection and spread unchecked. Immunotherapy drugs like Keytruda function by blocking these deceptive signals, essentially removing the cloak and making cancer cells visible to the immune system once again.
The advance in understanding this mechanism turned out to be so substantial that it won two scientists—James Allison and Tasuku Honjo—the Nobel Prize for Physiology or Medicine in 2018. Keytruda was one of the first immunotherapy drugs approved for clinical use, initially for melanoma before being expanded to address numerous other cancers. Today, it stands as the globally top-selling prescription medicine, with global sales totalling £22 billion in 2025. This remarkable commercial success demonstrates both the clinical efficacy of the drug and the growing acknowledgement of immunotherapy as a revolutionary approach to cancer care.
The study behind blocking cancer’s protective barriers
When cancer cells work to inhibit immune activity through their shielding proteins, Keytruda intervenes by blocking these blocking signals. This permits T-cells—the body’s frontline immune defenders—to identify cancer cells more readily and launch an effective response. By essentially removing the molecular invisibility cloak, the drug restores the immune system’s natural ability to locate and eradicate malignant cells, delivering patients a more targeted and potentially less damaging treatment option than standard chemotherapy treatments.
Genuine patient feedback regarding the new treatment
Shirley Xerxes, an 86-year-old from St Albans in Hertfordshire, was among the first NHS patients to experience the benefits of the injectable Keytruda at the Mount Vernon Cancer Centre near Watford. Her experience illustrates the transformative impact this new formulation offers. Where she previously spent over an hour in a hospital chair receiving her treatment through intravenous infusion, the injection now takes merely minutes. “It’s made such a difference and gives me greater opportunity to enjoy life, including enjoying more gardening time,” Shirley discussed her treatment experience, highlighting how the reduced hospital time results in better quality of life.
For numerous NHS cancer patients across England, the shift from drip-based administration to rapid injection marks a major improvement in quality of life. The simplified approach eradicates the extended delays and pain linked to prolonged infusions, allowing patients to get back to their everyday routines much faster. With approximately 14,000 cancer patients in England beginning Keytruda treatment annually, the majority are expected to transition to this quicker injectable form. This extensive implementation promises not just to boost individual patient experiences but also to release precious NHS facility resources and workforce time, delivering mutual benefits for both patients and the health service.
- Treatment duration decreased from over one hour to only a few minutes per appointment
- Injections given every three weeks as single-minute treatments or at six-weekly intervals as dual-minute treatments
- Patients gain considerably greater time to pursue daily activities and hobbies beyond hospital settings
Broader implications for NHS resources and future treatment
The rollout of injectable Keytruda represents a substantial workflow transformation for NHS cancer care. By reducing administration time from over an hour to mere minutes, hospitals can substantially boost patient throughput without increasing facilities or staffing levels. This operational benefit allows oncology departments to treat additional patients within existing clinic slots, ultimately reducing waiting times across the complete cancer care journey. Furthermore, the streamlined preparation procedure—removing the requirement for pharmacy teams to prepare individual infusion bags under controlled environments—enhances operational processes and reduces the risk of preparation errors, improving safety and efficiency across NHS trusts.
Beyond direct operational benefits, this development signals a broader shift towards patient-focused cancer treatment within the NHS. The time efficiencies achieved through injectable administration could be redirected towards other aspects of patient care, such as counselling, dietary advice, and survivorship initiatives. NHS England’s commitment to rolling out this treatment across the country demonstrates the organisation’s engagement with clinical innovation and its determination to provide world-class cancer services. As more immunotherapy medications become available in injectable form, the NHS is positioned to establish itself as a leader in contemporary, streamlined cancer treatment delivery.
Opportunity for community-led cancer care
The rapid delivery speed of injectable Keytruda creates promising possibilities for moving cancer care outside of traditional hospital settings. Local clinics and primary care practices equipped with appropriate resources could possibly deliver these treatments, bringing treatment closer to patients’ residences and reducing travel demands. This move to community-based delivery could turn out to be especially advantageous for older patients and those residing in remote areas, whilst simultaneously reducing demands on hospital cancer departments and allowing them to direct resources on more complex cases demanding expert oversight.
- Treatment could be delivered in local health centres and primary care practices with suitable facilities
- Minimised travel requirements for patients, notably those in isolated or countryside areas
- Hospital oncology departments enabled to focus on complex cases needing specialist expertise
Market dynamics and intellectual property concerns
Keytruda’s shift towards injectable form reaches a pivotal moment in the global pharmaceutical landscape. With annual revenues totalling £22 billion globally, the drug represents the top-selling prescription medicine, a position it has preserved through ongoing clinical advancement and regulatory approvals across several cancer conditions. The move towards injectable administration strengthens its competitive edge by addressing a significant pain point for patients—extended hospital stays—whilst also enhancing operational efficiency for health services. This advancement underscores how pharmaceutical companies are actively addressing real-world patient needs, not merely expanding their product portfolios but significantly redefining the treatment experience.
The introduction of injectable Keytruda also has implications for the NHS’s long-range drug procurement strategy and budget management. As the patent environment changes and biosimilar versions of pembrolizumab become available in coming years, the injectable formulation may influence negotiation discussions and market pressures. NHS England’s swift adoption of this novel delivery approach places the healthcare system in a strong position, possibly obtaining advantageous terms and negotiating leverage with drug makers. The streamlined administration also reduces healthcare expenses outside of the medication cost itself, such as lower staffing requirements, briefer clinical visits, and decreased facility usage—factors that reinforce the financial case for broad deployment across England’s cancer treatment facilities.